MARKET

BSTG

BSTG

Biostage
OTCMQB
6.85
+1.30
+23.42%
Closed 15:33 10/06 EDT
OPEN
5.93
PREV CLOSE
5.55
HIGH
7.00
LOW
5.93
VOLUME
3.44K
TURNOVER
23.14K
52 WEEK HIGH
9.00
52 WEEK LOW
1.010
MARKET CAP
79.57M
P/E (TTM)
-7.4182
1D
5D
1M
3M
1Y
5Y
BRIEF-Biostage Reports Corporate Highlights And Second Quarter Financial Results
BRIEF-Biostage Reports Corporate Highlights And Second Quarter Financial Results
Reuters · 08/04 21:51
Biostage GAAP EPS of -$0.12
Biostage press release (<a href="https://seekingalpha.com/symbol/BSTG?u...
Seekingalpha · 08/04 21:39
Biostage Schedules Conference Call and Webcast for Q2 2022 Results
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence...
PR Newswire · 08/04 12:00
Biostage Announces Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Journal of Biomechanics
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience repairing the esophagus following cancer surgery and FDA approval to commence a clinical trial of the Biostage Esopha...
PR Newswire · 06/15 12:30
Insider Buy: Biostage
MT Newswires · 05/23 16:03
Biostage reports Q1 results
Biostage press release (OTC:BSTG): Q1 GAAP EPS of -$0.20. As of March 31, 2022, the company had operating cash on-hand of $0.7 million. Expects that its current cash will be sufficient to fund
Seekingalpha · 05/16 20:17
Cell-therapy biotechnology company Biostage raises ~$5.1M to advance clinical trial
Cell-therapy biotechnology company, Biostage (OTC:BSTG) raises ~$5.1M from new and existing investors in a private placement of its shares.  The funds will be used to accelerate the clinical development of Biostage's
Seekingalpha · 05/13 14:00
Biostage Schedules Conference Call and Webcast for Q1 2022 Results
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence...
PR Newswire · 05/10 12:30
More
About BSTG
Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient's own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.

Webull offers kinds of Biostage Inc stock information, including OTCMQB:BSTG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BSTG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BSTG stock methods without spending real money on the virtual paper trading platform.